Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor.
Immune mechanisms and the renin-angiotensin system are implicated in preeclampsia. We investigated 25 preeclamptic patients and compared them with 12 normotensive pregnant women and 10 pregnant patients with essential hypertension. Antibodies were detected by the chronotropic responses to AT1 receptor-mediated stimulation of cultured neonatal rat cardiomyocytes coupled with receptor-specific antagonists. Immunoglobulin from all preeclamptic patients stimulated the AT1 receptor, whereas immunoglobulin from controls had no effect. The increased autoimmune activity decreased after delivery. Affinity-column purification and anti-human IgG and IgM antibody exposure implicated an IgG antibody directed at the AT1 receptor. Peptides corresponding to sites on the AT1 receptor's second extracellular loop abolished the stimulatory effect. Western blotting with purified patient IgG and a commercially obtained AT1 receptor antibody produced bands of identical molecular weight. Furthermore, confocal microscopy of vascular smooth muscle cells showed colocalization of purified patient IgG and AT1 receptor antibody. The protein kinase C (PKC) inhibitor calphostin C prevented the stimulatory effect. Our results suggest that preeclamptic patients develop stimulatory autoantibodies against the second extracellular AT1 receptor loop. The effect appears to be PKC-mediated. These novel autoantibodies may participate in the angiotensin II-induced vascular lesions in these patients.
Wallukat
G
G
Franz Volhard Clinic at the Max Delbrück Center for Molecular Medicine, Humboldt University of Berlin, 13122 Berlin, Germany.
Homuth
V
V
Fischer
T
T
Lindschau
C
C
Horstkamp
B
B
Jüpner
A
A
Baur
E
E
Nissen
E
E
Vetter
K
K
Neichel
D
D
Dudenhausen
J W
JW
Haller
H
H
Luft
F C
FC
D000595:Amino Acid Sequence; D000804:Angiotensin II / Q000494:pharmacology; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001323:Autoantibodies / Q000276:immunology*; D002478:Cells, Cultured; D005260:Female; D006352:Heart Ventricles / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology; D007075:Immunoglobulin M / Q000494:pharmacology; D008969:Molecular Sequence Data; D009131:Muscle, Smooth, Vascular / Q000276:immunology; D009200:Myocardial Contraction / Q000187:drug effects / Q000276:immunology; D009281:Naphthalenes / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D049590:Postpartum Period; D011225:Pre-Eclampsia / Q000276:immunology*; D011247:Pregnancy; D051381:Rats; D017208:Rats, Wistar; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D011945:Receptors, Angiotensin / Q000819:agonists* / Q000276:immunology
D057911:Angiotensin Receptor Antagonists; D001323:Autoantibodies; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D009281:Naphthalenes; D010446:Peptide Fragments; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D011945:Receptors, Angiotensin; D000804:Angiotensin II; C058819:calphostin C